Chairman of Sinovac Yin Weidong’ Speech at the International Forum on Covid-19 Vaccine Cooperation Conference
Your Excellency Wang Yi , State Councilor and Foreign Minister;
Your Excellencies Ministers, Representatives of International Organizations;
Distinguished Partners of Sinovac, Ladies and Gentlemen,
It gives me great pleasure to attend this International Forum on Covid-19 Vaccine Cooperation Conference today to seek a better future all together.
With the support of the governments of many countries and your strong leadership, Sinovac's COVID-19 vaccine has been granted an emergency use or conditional marketing authorization in more than 50 countries as well as being included in the emergency use list of World Health Organization. Sinovac has signed nearly 900 million vaccine cooperation agreements with 20 countries outside of China this year. These vaccines are not only manufactured in China, but are also jointly produced in BioFarma in Indonesia, Butantan Institute in Brazil as well as countries in Turkey, Malaysia, and Egypt.
Currently, the global Covid-19 epidemic is still spreading. A major challenge we are facing is to establish a herd immunity which requires a high vaccination coverage, however, the vaccination rate in many developing countries is still very low. Another major challenge is the new variants. Recently, a lots of research data show that the Delta strain has a higher transmission rate, and the mutated virus is challenging the vaccine effectiveness.
Facing these two major challenges, Sinovac needs to cooperate with governments, Disease Prevention and Control Departments and scientists to provide solutions.
Firstly, the safety of the vaccine is an important factor in increasing the vaccination rate.
In high-risk areas or periods, people are likely to put the safety of vaccines in a secondary concern, but now we all see that when the safety of vaccines does not meet the expectations of the general public, it is difficult to make the vaccination coverage to achieve the desired goal of herd immunity. Therefore, global vaccine suppliers should regard vaccine safety as the most important indicator.
So far, more than 1 billion doses of CoronaVac® have been administered worldwide, and it says CoronaVac® is one of the safest Covid-19 vaccines. Sinovac will ensure the safety of CoronaVac® and promote higher vaccination rates in all countries, so that we can shoot more "bullets” to control the Covid-19 epidemic.
Secondly, take effective measures to deal with new variants.
Sinovac has completed the study of the third dose of CoronaVac® on booster immunization. The third dose of vaccination is still as safe as the first and second doses. At the same time, the level of neutralizing antibodies can be rapidly increased within a week. Scientists from the Chinese Academy of Sciences will soon publish their new discoveries in scientific journal. After booster shot, the vaccine efficacy on the new variants is improved. Real-world Study after booster shot has been carried out in Turkey, Chile and other countries, and the results will be published soonest.
Sinovac will also submit our clinical research and emergency use applications for the Gamma and Delta strains of CoronaVac® to the National Medical Products Administration in coming days. Sinovac has sufficient production capacity to provide CoronaVac® developed and based on variants.
In conclusion, Improving the efficacy of CoronaVac® to make sure our "Bullets do not miss the target, is the direction of Sinovac’s continuous efforts, and we believe that we can make it happen."
The Covid-19 can travel across borders, and the battle against the epidemic for human beings constantly changing. Cooperation in vaccine scientific research and development should be an eternal winning strategy. Sinovac looks forward to partnering with every country with more trust for longer-term cooperation. Sinovac will provide more vaccines to more countries!
科兴控股生物技术有限公司（Sinovac Biotech Ltd.，SINOVAC科兴）是中国领先的生物高新技术企业，以“为人类消除疾病提供疫苗”为使命，致力于人用疫苗及其相关产品的研究、开发、生产和销售，为全球疾病预防控制提供服务。